Onyia Jude

Onyia Jude, chief scientific officer at Neurocrine Biosciences (NBIX), has been a consistent seller of company stock over the past year, with no open-market purchases on record. Across 41 total Form 4 filings spanning two companies, his transactions amount to roughly $14.8 million in sales, entirely concentrated in NBIX. The most recent activity shows a continuation of that pattern: on June 1, 2026, he sold shares valued at approximately $1.76 million, following a $1.71 million sale on May 27, 2026. Both sales were paired with option exercises of $932,140 each, a mechanical step that typically precedes a disposition. His largest single transaction came on July 9, 2025, when he sold about $7.8 million worth of NBIX stock, also tied to an option exercise worth roughly $5.07 million. The selling bias is unambiguous, but the filings also reveal a mix of non-discretionary and compensatory activity that tempers the signal. In February 2026, Jude received multiple stock awards (coded as "A") with no cash value, alongside tax-withholding transactions (coded as "F") totaling roughly $1.7 million — automatic share surrenders that reduce holdings without a market decision. He also made several gifts (coded as "G") in September 2025, August 2025, and June 2026, which involve no cash consideration. The only other company in his filing history is Voyager Therapeutics (VYGR), where a June 9, 2026 award was recorded at zero value, indicating compensation rather than an investment signal. Overall, Jude's Form 4 history shows a clear directional trend: he has not bought a single share on the open market, while selling millions of dollars in NBIX stock over the past year. The recent cluster of sales in late May and early June 2026, each in the $1.7–1.8 million range, suggests an ongoing program of monetizing equity compensation rather than a one-off event. The absence of any purchase activity across both companies reinforces a net disposition posture, though the prevalence of option exercises, tax withholdings, and gifts means the raw sales figures overstate discretionary selling.